Infosys completes acquisition of BASE life science

The acquisition reaffirms Infosys’ commitment to help global life sciences companies

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors

Biological E. announces CDSCO recommendation of its infant’s vaccine

Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)

Zydus announces Phase IV DREAM-CKD trial of Desidustat in patients with CDK induced anemia

The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.

Moderna sues Pfizer, BioNTech for mRNA patent infringement

Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016

Moderna files for emergency use of BA.4/BA.5 Omicron booster

Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September

Lupin and I'rom signs licensing agreement for Denosumab biosimilar for Japan

ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial

Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.